Providing vaccines against human papillomavirus to adolescent girls in the Americas: Battling cervical cancer, improving overall health

Health Affairs

Volumn 30, Issue 6, 2011, Pages 1089-1095

  Luciani, Silvana ^a   Prieto Lara, Elisa ^a   Vicari, Andrea ^a  

^a PAN AMERICAN HEALTH ORGANIZATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADOLESCENT HEALTH; ARTICLE; CANCER SCREENING; CANCER THERAPY; DRUG EFFICACY; FEMALE; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; MEDICAL LITERATURE; NUTRITION; PAPILLOMAVIRUS INFECTION; REPRODUCTIVE HEALTH; UTERINE CERVIX CANCER; WART VIRUS; WESTERN HEMISPHERE; WOMEN'S HEALTH;

ADOLESCENT; ALPHAPAPILLOMAVIRUS; CARIBBEAN REGION; CENTRAL AMERICA; FEMALE; HUMANS; MASS SCREENING; NORTH AMERICA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SOUTH AMERICA; UTERINE CERVICAL NEOPLASMS;

EID: 79959504372     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.0315     Document Type: Article

References (30)

1. Tambini G, Andrus JK, Fitzsimmons JW, Roses Periago M. 2006 Regional immunization programs as a model for strengthening cooperation among nations. Pan Am J Public Health. 20(1), 54-9.
2. Andrus JK, Fitzsimmons J. 2005 Introduction of new and underutilized vaccines, sustaining access, disease control, and infrastructure development. PLoS Med. 2(10), e286.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010 GLOBOCAN, cancer incidence and mortality worldwide in 2008 [Internet]. Lyon (France), International Agency for Research on Cancer; [cited 2011 Mar 3]. Available from, http://globocan.iarc.fr.
4. WHO/ICO Information Centre. Human papillomavirus and related cancers in Americas, summary report [Internet]. Barcelona, HPV Information Centre; 2010 Sep 15 [cited 2011 Mar 3]. Available from, http://apps.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/XMX.pdf?CFID=4979257& CFTOKEN=94419543.
5. World Health Organization. Human papillomavirus and HPV vaccines, technical information for policymakers and health professionals [Internet]. Geneva, WHO; 2007 [cited 2011 May 9]. (WHO/IVB/07.05). Available from, http://www.who.int/reproductivehealth/publications/cancers/IVB_07.05/en/index.html.
6. De Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer, a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11), 1048-56.
7. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. SEER cancer statistics review, 1975-2008 [Internet]. Bethesda (MD), National Cancer Institute; 2011 Apr 15 [cited 2011 May 9]. Available from, http://seercancer.gov/csr/1975_2008/.
8. Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Piñeros M. Burden and trends of type-specific human papillomavirus infections and related disease in the Latin America and Caribbean region. Vaccine. 2008;26(Suppl 11), L1-15.
9. Kitchener HC, Castle PE, Cox JT. Achievements and limitations of cervical cytology screening. Vaccine. 2006;24(Suppl 3), S63-70.
10. Murillo R, Almonte M, Pereira A, Ferrer E, Gamboa OA, Jerónimo J, et al. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine. 2008; 26(Suppl 11), L37-48.
11. World Health Organization. Human papillomavirus vaccines, WHO position paper. Weekly Epidemiological Record [serial on the Internet]. 2009 Apr 10 [cited 2011 May 9]. Available from, http://www.who.int/wer/2009/wer8415.pdf.
12. Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women, a systematic review & meta-analysis. BMC Infect Dis. 2011;11, 13.
13. Goldie SJ, O'Shea M, Diaz M, Kim SY. Benefits, cost requirements, and cost-effectiveness of the HPV16, 18 vaccine for cervical cancer prevention in developing countries, policy implications. Reprod Health Matters. 2008;16(32), 86-96.
14. Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine. 2008; 26(Suppl 11), L59-72.
15. Luciani S, Andrus JK. A Pan American Health Organization strategy for cervical cancer prevention in Latin America and the Caribbean. Reprod Health Matters. 2008;16(32), 59-66.
16. Schwartz JL. HPV vaccination's second act, promotion, competition, and compulsion. Am J Public Health. 2010;100(10), 1841-4.
17. Colgrove J, Abiola S, Mello MM. HPV vaccination mandates-lawmaking amid political and scientific controversy. N Engl J Med. 2010; 363(8), 785-91.
18. Winkler JL, Wittet S, Bartolini RM, Creed-Kanashiro HM, Lazcano-Ponce E, Lewis-Bell K, et al. Determinants of human papillomavirus vaccine acceptability in Latin America and the Caribbean. Vaccine. 2008;26(Suppl 11), L73-9.
19. Stupiansky NW, Rosenthal SL, Wiehe SE, Zimet GD. Human papillomavirus vaccine acceptability among a national sample of adult women in the USA. Sex Health. 2010;7(3), 304-9.
20. Lee FH, Paz-Soldan VA, Carcamo C, Garcia PJ. Knowledge and attitudes of adult Peruvian women vis-à-vis Human Papillomavirus (HPV), cervical cancer, and the HPV vaccine. J Low Genit Tract Dis. 2010;14(2), 113-7.
21. Pollack AE, Balkin M, Edouard L, Cutts F, Broutet N, WHO/UNFPA Working Group on Sexual and Reproductive Health and HPV Vaccines. Ensuring access to HPV vaccines through integrated services, a reproductive health perspective. Bull World Health Organ. 007;85(1), 57-63.
22. Andrus JK, Lewis MJ, Goldie SJ, García PJ, Winkler JL, et al. Human papillomavirus vaccine policy and delivery in Latin America and the Caribbean. Vaccine. 2008; 26(Suppl 11), L80-7.
23. Bartolini RM, Drake JK, Creed-Kanashiro HM, Díaz-Otoya MM, Mosqueira-Lovón NR, Penny ME, et al. Formative research to shape HPV vaccine introduction strategies in Peru. Salud Publica Mex. 2010; 52(3), 226-33.
24. Cervical Cancer Action. Progress in cervical cancer prevention, the CCA report card [Internet]. Seattle (WA), CCA; 2011 Apr [cited 2011 May 9]. Available from, http://www.cervicalcanceraction.org/pubs/CCA_reportcard_med-res.pdf.
25. Huang CJ. Human papillomavirus vaccination-reasons for caution. N Engl J Med. 2008;359, 861-2.
26. De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine. 2010;28(38), 6247-55.
27. Franco EL, Tsu V, Herrero R, Lazcano-Ponce E, Hildesheim A, Muñoz N, et al. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Vaccine. 2008;26(Suppl 11), L88-95.
28. Dobson S, Dawar M, Kollman T, McNeil S, Halperin S, Langley J. A two dose HPV vaccine schedule in girls, immunogenicity at 24 months. Poster presented at, Twenty-Sixth International Papillomavirus Conference and Clinical and Public Health Workshops; 2010 Jul 3-8; ontreal, QC.
29. Peres J. For cancers caused by HPV, two vaccines were just the beginning. J Natl Cancer Inst. 2011; 103(5), 360-2.
30. Jauregui B, Sinha A, Clark AD, Bolanos BM, Resch S, Toscano CM, et al. Strengthening the technical capacity at country-level to make informed policy decisions on new vaccine introduction, lessons learned by PAHO's ProVac Initiative. Vaccine. 2011;29(5), 1099-106.